Or­biMed dou­bling down on Asia biotech bets with $450M fund

Over the last nine years Or­biMed has gath­ered more than a half bil­lion dol­lars ear­marked for its Asia group’s life sci­ences in­vest­ments. And now it’s dou­bling down, shoot­ing for a record $450 mil­lion fund that could eas­i­ly take the to­tal above $1 bil­lion.

Or­biMed Asia dis­closed its in­ter­est in the new fund in a fil­ing with the SEC, a lit­tle more than two years af­ter grab­bing $325 mil­lion for its sec­ond fund. Re­cent in­vest­ments in­clude CBT Phar­ma­ceu­ti­cals, led by CEO San­jeev Red­kar, which is work­ing on check­point in­hibitors. Or­biMed al­so par­tic­i­pat­ed in the $100 mil­lion round for Shang­hai-based Zai Lab ear­ly last year. Ear­li­er rounds sup­port­ed Sha­sun — merged in­to Strides Sha­sun — and Mum­bai-based Bharat Serums.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.